Tegafu (UFT, Uftoral)
Chemotherapy · Approved since 2001
Description
Tegafur is an oral fluoropyrimidine chemotherapy agent used in the treatment of colorectal cancer, typically administered in combination with uracil and leucovorin (folinic acid). It serves as a prodrug of 5-fluorouracil (5-FU) and is commonly used in adjuvant therapy for completely resected stage III colon cancer. Tegafur is also employed in neoadjuvant treatment protocols for rectal adenocarcinoma, often combined with radiation therapy.
Mechanism of Action
Tegafur is converted to 5-fluorouracil in tumor tissues through enzymatic metabolism, where it inhibits thymidylate synthase, a key enzyme required for DNA synthesis and repair. This inhibition leads to depletion of thymidine triphosphate pools and incorporation of fluorinated nucleotides into DNA and RNA, ultimately resulting in cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | UFT, Uftoral |
| Category | Chemotherapy |
 Status | FDA Approved |
| Administration | Oral |
| Year Approved | 2001 |
| Clinical Trials | 6 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.